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Background: Impairment of homologous recombination (HR) is found in close to 50 % of ovarian and breast cancer.
Tumors with BRCA1 mutations show increased expression of the Insulin-like growth factor type 1 receptor (IGF-1R). We
previously have shown that inhibition of IGF-1R results in growth inhibition and apoptosis of ovarian tumor cells. In
the current study, we aimed to investigate the correlation between HR and sensitivity to IGF-1R inhibition. Further,
we hypothesized that IGF-1R inhibition might sensitize HR proficient cancers to Poly ADP ribose polymerase
(PARP) inhibitors.
Methods: Using ovarian and breast cancer cellular models with known BRCA1 status, we evaluated their HR
functionality by RAD51 foci formation assay. The 50 % lethal concentration (LC50) of Insulin-like growth factor type 1
receptor kinase inhibitor (IGF-1Rki) in these cells was assessed, and western immunoblotting was performed to
determine the expression of proteins involved in the IGF-1R pathway. Moreover, IGF-1R inhibitors were added on HR
proficient cell lines to assess mRNA and protein expression of RAD51 by qPCR and western blot. Also, we explored the
interaction between RAD51 and Insulin receptor substance 1 (IRS-1) by immunoprecipitation. Next, combination effect
of IGF-1R and PARP inhibitors was evaluated by clonogenic assay.
Results: Cells with mutated/methylated BRCA1 showed an impaired HR function, and had an overactivation of
the IGF-1R pathway. These cells were more sensitive to IGF-1R inhibition compared to HR proficient cells. In
addition, the IGF-IR inhibitor reduced RAD51 expression at mRNA and protein levels in HR proficient cells, and
sensitized these cells to PARP inhibitor.
Conclusion: Targeting IGF-1R might lead to improved personalized therapeutic approaches in cancer patients
with HR deficiency. Targeting both PARP and IGF-1R might increase the clinical efficacy in HR deficient
patients and increase the population of patients who may benefit from PARP inhibitors.
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Ovarian cancer is the most lethal gynecologic malig-
nancy. Despite the fact that 70–80 % of ovarian can-
cer patients initially respond to standard treatments,
most will relapse and ultimately die of the disease [1].
Having reached a stage of stagnation with conven-
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persistent/recurrent tumor cells.
Further, primary triple negative breast cancer (TNBC),
which are defined by the lack of expression of estrogen
receptors, progesterone receptors and HER2 gene ampli-
fication and overexpression, represent approximately
16 % of all breast cancers and exhibit poor clinical out-
come due to aggressive behavior and lack of effective
therapies [2].
Up to 30 % of ovarian cancer and TNBC patients show
functional impairment of BRCA1/2 genes [3, 4] ands distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Amin et al. BMC Cancer  (2015) 15:817 Page 2 of 14women carrying BRCA1/2 germline mutations are at an
increased risk of developing ovarian and breast cancer
[5–8]. These mutations in BRCA1/2 genes exhibit im-
paired cellular ability to repair double-stranded DNA
breaks via the homologous recombination (HR) repair
pathway, leading to reduced RAD51 foci formation fol-
lowing DNA damage [9, 10]. Moreover, in cancer cells
with loss of function of proteins involved in HR includ-
ing BRCA1/2, but also RAD51, ATM or ATR, Poly
(ADP-ribose) polymerase (PARP) inhibition, which inter-
feres with single stranded DNA repair, has been shown
to induce specific cancer cell killing, called synthetic le-
thality [11].
BRCA1 has been shown to directly affect the IGF-1R
pathway [12] and studies have suggested that BRCA1/2
deficient breast cancer cells are associated with elevated
expression of Insulin like growth factor-1 receptor (IGF-
1R) [13–15]. IGF-1R are widely expressed on normal
and neoplastic cells [13, 16–20], and an IGF-1 autocrine
loop was described in ovarian and breast cancer cells
[21–23]. Inhibition of the IGF-1 pathway suppresses
ovarian cancer cell survival in vitro [22, 24, 25] and in
vivo in xenograft models [26], and its expression is
associated with cancer progression [17, 27]. Moreover,
IGF-1 promotes proliferation and survival of TNBC cells
[28], and is involved in tumor metastasis and invasion
[29–31], increasing the appeal of targeting the IGF-1R
pathway. Finally, an association between inhibition of
the IGF-1R and suppression of the HR DNA repair path-
way has been described in prostate cancer [32] and non-
small cell lung cancer cells exposed to radiation [33]. In
this study, we evaluate the interactions between HR and
IGF-1R inhibition and whether IGF-1R inhibition can




The epithelial ovarian cancer cell lines SKOV3,
UWB1.289 (ATCC, Manassas, VA, USA), IGROV1 (NCI),
OVCAR8 (Biomiga, San Diego, CA USA) were used in
this study. SKOV3, IGROV1, OVCAR8 were grown in
RPMI-1640 medium supplemented with 10 % fetal bovine
serum (FBS), 2 mM glutamine, and 10 μg/ml gentamicin
and UWB1.289 was grown in 50 % MEGM medium (sup-
plemented with hEGF, BPE, insulin, hydrocortisone), 50 %
RPMI-1640 (supplemented with 10 % FBS, 2 mM glutam-
ine) and 10 μg/ml gentamicin. The breast cancer cell lines
BT20, MDA-MB-231, MDA-MB-436, HCC1937 were ob-
tained from ATCC, Manassas, VA, USA. SUM149PT cell
line was obtained from Asterand, Detroit, MI, USA. BT20
and MDA-MB-231 were grown in DMEM supplemented
with 10 % FBS, and 10 μg/ml gentamicin. MDA-MB-431
and HCC1937 were grown in RPMI-1640 mediumsupplemented with 10 % FBS, and 10 μg/ml gentamicin.
SUM149PT was grown in RPMI-1640 medium supple-
mented with 10 % FBS, 10 μg/ml gentamicin and growth
factors (insulin, hydrocortisone). According to published
data, the BRCA1 gene profile status of these cells is as fol-
low: SKOV3, BT20, MDA-MB-231 (wild type BRCA1
gene); IGROV1 (heterozygous 280delA BRCA1 mutation);
OVCAR8 (carrying methylated BRCA1 gene); UWB1.289
(homozygous 2594delC BRCA1 gene mutation), MDA-
MB-436 (homozygous 5396 + 1G >A BRCA1 mutation);
HCC1937 (homozygous 5382insC BRCA1 mutation);
SUM149PT (homozygous 2288delT BRCA1 mutation)
[34, 35]. Each cell line was passaged every 4 to 6 days. All
cells were maintained at 37 °C in a 5 % CO2, 95 % air at-
mosphere incubator. All assays were performed in the re-
spective cell medium.
Patient tumor-derived ovarian cancer cells labeled
GOC31, GOC17, GOC15, GOC13, GNOV1, GOC23 were
isolated in our laboratory from six surgical specimens, all
from high grade (grade 3) stage 3/4 serous ovarian cancer.
This study was approved by the ethic committee of Jewish
General Hospital (JGH) and all patients participating in
this study gave informed consent in accordance with the
JGH ethics committee regulations (protocol#03-041). Two
of the epithelial cell lines (GOC23 and GNOV1) were de-
rived from patients carrying the 5385insC BRCA1 germ-
line mutations. Presence of the mutations in these cell
lines was confirmed by the molecular pathology depart-
ment. Primary cell lines were grown in OSE medium sup-
plemented with 20 % FBS and growth factors (insulin,
EGFR, hydrocortisone, BPE). The cells were routinely pas-
saged every 4 to 6 days. All cells were maintained at 37 °C
in a 5 % CO2, 95 % air atmosphere incubator. All assays
were performed in the respective cell medium.
Survival assays
The clonogenic assay was used to determine survival frac-
tion of cells [36]. Briefly, 350–800 cells were plated in 6-
well flat bottom cell culture plates in duplicates. Twenty-
four hours after plating, cells were washed and fresh
medium was added in the presence or absence of increas-
ing doses of IGF-1Rki (BMS-536924) and PARP inhibitor
(olaparib) alone and in combination. Media containing the
drug was refreshed on day 4. Colonies were fixed and
stained after 7 days of treatment with 1.5 ml of 6.0 %
glutaraldehyde and 0.5 % crystal violet and colonies
were counted using the GelCount, Optronix. The
surviving fraction (SF) of cells was calculated as follows:
SF ¼ Number of colonies formed after treatmentNumber of cells seeded x Plating Efficiency , where Plating
Efficiency ¼ Number of colonies formed in controlNumber of cells seeded [36]. The inter-
action between IGF-1Rki and PARP inhibitor was assessed
using the multiple drug effects analysis method of Chou
and Talalay [37]. This method quantitatively describes the
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than 1 indicating synergistic interactions, values greater
than 1 indicating antagonistic interactions, and values
equal to 1 indicating additive interactions.
The Alamar Blue assay was used to determine cell via-
bility. Monolayers of 2000 cells were plated into 96-well
flat-bottom cell culture plates in triplicates. Twenty-four
hours after plating, when the cells had attached and
reached ~40 % confluency, cells were washed and the
medium was replaced with medium containing 1 % FBS
with increasing doses of IGF-1Rki for 72 h. Controls in-
cluded equal amount of DMSO. Cell viability was
assessed by visual inspection of the plates and by using
the AlamarBlue colorimetric assay. AlamarBlue (Invitro-
gen, Burlington,Ontario) assay allows quantitative ana-
lysis of cell viability via the innate metabolic activity that
results in a chemical reduction of AlamarBlue that
changes from the oxidized (blue) form to the reduced
(pink) form. After cells were treated, 6 μl of AlamarBlue
was added into each well. When the color of the dye
changed (approximately 4 h), plates were read in an
ELISA plate reader at 2 different wavelengths, 562 nm
and 620 nm to plot the graph. Percentage of reduced
AlamarBlue was calculated using the following equation:
Reduced AlamarBlue % = (A562 −A620) × Rо; where
A562 and A620 are sample absorbencies minus the
media blank; Rо ¼ AO562AO620, where AO562 is the absorbance
of oxidized form at 562 nm, and AO620 is the absorb-
ance of oxidized form at 620 nm.Fig. 1 BRCA1 expression in ovarian and breast cancer cells. Reduced expressi
and b) protein levels using RT-qPCR and western blot analysis, respectively. BR
using western blot analysis. Results shown are one representative experimentImmunofluorescence analysis
Cells were seeded in 6-well plates at a density of 1 × 105
cells / well on a sterile coverslip. Twenty-four hours after
plating, when the cells had attached and reached ~60 %
confluency, cells were washed and the medium was re-
placed with medium containing 1 μg/ml cisplatin for 1 h
and allowed to recover for ~6 h. In another setting, the
cells were treated with medium containing 5 μM IGF-
1Rki for 24 h, followed by 1 μg/ml cisplatin treatment for
1 h and allowed to recover for ~6 h. The cells were then
washed in phosphate-buffered saline (PBS) and fixed using
4 % formaldehyde. They were subsequently permeabilized
with 0.2 % Triton-X 100 in PBS for 15 min. After blocking
with 2 % BSA/PBS for 1 h at room temperature, cells were
incubated with primary antibodies: RAD51 (Santa Cruz
Biotechnology, CA, USA; 1:200) in blocking buffer for
60 min at room temperature. Cells were then washed in
PBS and incubated with AlexaFlour 488chicken anti-
rabbit IgG secondary antibody (Invitrogen, CA, USA;
1:500) for 30 min. Finally, cells were counterstained with
4′, 6-diamidino-2-phenylindole (DAPI) for 5 min before
the final wash and photographed using LEICA; DMI6000B
microscope.
Protein extraction and western blot analysis
Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (25 mM Tris∙HCl, pH 7.6, 150 mM NaCl,
1 % NP-40, 0.25 % sodium deoxycholate, 0.1 % SDS)
supplemented with protease inhibitor cocktail tablet andon of BRCA1 was observed in SKOV3 transfected with shBRCA1: a) mRNA
CA1 protein expression status in c) ovarian and d) breast cancer cells,
out of three independent experiments
Fig. 2 (See legend on next page.)
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Fig. 2 Reduced RAD51 foci formation in cancer cells with low/absent BRCA1 expression. Cells were treated with 1ug/ml cisplatin for one
hour, allowed to recover for six hours and then fixed for immunofluorescence. Immunofluorescence staining images of RAD51 foci in
ovarian (a, c) and breast (e) cancer cells with respect to the BRCA1 protein expression are shown at 100X magnification. Quantitative
representation of the percentage of cells with positive RAD51 foci is shown in fig (b, d, f). Cells with >5 foci/nucleus were considered
positive. Results represent the average of three independent experiments. *p < 0.05
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Diagnostics, Mannheim, Germany). Total protein con-
tent was measured according to Pierce BCA protein
assay kit (Thermo Scientific, Rockford, IL, USA). Then
protein lysates (50 μg) were resolved electrophoretically
on denaturing SDS-polyacrylamide gels, and transferred
to 0.45 μm nitrocellulose membranes. After blocking in
5 % milk in PBST, membranes were probed with the fol-
lowing primary antibodies: anti-mouse BRCA1(Ab-1)
(Calbiochem), anti-mouse p-ATM (Ser1981) (Millipore),
anti-rabbit ATM (D2E2), anti-rabbit p-IGF-1R beta
(Y1135/1136), anti-rabbit IGF-1R beta (111A9), anti-
rabbit p-IRS1(S612), anti-rabbit IRS1, anti-rabbit p-
AKT(S473), anti-rabbit AKT, anti-rabbit p-S6 (Ser235/
236), anti-rabbit S6 (5G10), anti-rabbit beta-actin (Cell
signalling, Danvers, MA ,USA) and anti-rabbit RAD51
(Santa Cruz Biotechnology, Dallas,Texas, USA). Immu-
nobloted proteins were visualized using horseradish per-
oxidise (HRP)-conjugated secondary antibodies and
antigen-antibody complexes were detected using the
ECL system.Immunoprecipitation analysis
Clarified protein lysates (300–500 μg/ml) were pre
cleared with 25 μl of protein G-magnetic beads (EMD
Millipore, ON, Canada), followed by 1 h incubation at
4 °C. Magnetic field was applied for 30 s to pull beads to
the side of the tube and supernatant was pipetted to a
clean tube. Then 1–5 μg of antibody; anti-rabbit RAD51
(Santa Cruz Biotechnology) or anti-rabbit IRS-1
(D23G12) (Cell signalling), was added to crude cell lys-
ate, followed by overnight incubation at 4 °C. The next
day, 25 μl of protein G magnetic beads suspension was
added and incubated for 2 h at 4 °C. Then magnetic field
was applied and supernatant was removed and dis-
carded. Beads pellet was washed with 500 μl of RIPA
buffer by gentle vortex. Again magnetic field was applied
and supernatant was removed and discarded (RIPA buf-
fer wash was repeated 2 more times). Beads pellet was
then resuspended in 25 μl of 2X SDS Sample Loading
Buffer and incubated at 95 °C for 10 min. After centri-
fuge, magnetic field was applied to sample, and super-
natant was loaded on SDS-PAGE gel for electrophoresis.
Separated proteins were transferred to membranes.
Membranes were then probed with a specific antibodyfollowed by peroxidase-conjugated appropriate second-
ary antibody and visualization by ECL.shBRCA1 transfection
SKOV3 cells were seeded in 6-well flat-bottom cell cul-
ture plates at a density of 0.25x106cells / well. Lipofecta-
mine (Invitrogen, Burlington, Ontario, Canada) (1:1) was
mixed with control shRNA and BRCA1 shRNA separ-
ately in RPMI-1640 with no FBS. Following 30 min of
incubation at room temperature, both negative and
BRCA1 shRNA were added to their respective wells.
The cells were incubated at 37 °C for 5 h. Pools of stably
transfected cells were selected using 2 mg/ml puromycin
for up to a week.Gene expression analysis
SKOV3 and BT20 cells were treated with IGF-1Rki (1–
5 μM) for 12 h, 16 h and 24 h time points. RNA was iso-
lated from cells using Quick-RNA Mini prep kit (Zymo
research, CA, USA). cDNA was synthesized using M-
MLV retrotranscriptase enzyme. Template cDNA was
added to Maxima SYBR Green/ROX qPCR master mix
(2X) (Thermo Scientific, MA,USA) with RAD51 and
36B4 primers. Quantification of gene expression was
performed using the Applied Biosystems 7500 fast real-
time PCR system (life technologies).Statistical analysis
Statistical analysis was performed using Prism and the
non-parametric two-tailed paired T-Test. P < 0.05 was
considered statistically significant.Results
Determination of BRCA1 expression in cancer cells
SKOV3 cells transfected with shBRCA1 were assessed
by RT-PCR and western blot. As shown in Fig. 1a and b,
we found reduced levels of BRCA1 mRNA and protein
in the transfected SKOV3 cell line. We next evaluated
BRCA1 protein expression in ovarian and breast cancer
cells, as shown in Fig. 1c,d and confirmed previously
published data where OVCAR8, UWB1.289, MDA-
MB436, HCC1937 and SUM149T are BRCA1-deficient
[34, 35].
Fig. 3 (See legend on next page.)
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Fig. 3 HR deficient ovarian cancer cell lines derived from patients show higher sensitivity to IGF-1Rki. Over activation of IGF-1R pathway was observed
by western blotting in cells having no BRCA1 expression (a). HR functionality was determined using RAD51 foci (green) formation following cisplatin
treatment. A representative image (magnification 100X) is shown in (b), and quantification in (c) (cells with >5 RAD51 foci/nucleus were considered
positive). d LC50 of the IGF-1Rki was determined in these cells using the Alamar survival assay e) Correlation was assessed between the
LC50 of IGF-1Rki and the HR functionality of cells. The HR functionality was determined by the difference between the % of cells forming RAD51 foci
after cisplatin treatment and the control. All the results represent the average of three independent experiments. *p value <0.05
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absent BRCA1 protein expression
We then assessed the correlation of BRCA1 protein ex-
pression and HR functionality in these cells. To assess
HR functionality, we evaluated the RAD51 foci forma-
tion upon DNA damage with one hour treatment of
1 μg/ml cisplatin, by immunofluorescence, as an indica-
tion of cells’ ability to repair DNA double strand break
[38]. We observed the reduction in level of nuclear
RAD51 foci formation after cisplatin treatment in cells
having low or absent BRCA1 protein expression, as
shown in Fig. 2a-f, suggesting a lower capacity of DNA
repair through HR.
We performed similar experiments in patient-derived
ovarian cancer cells. Among the six cell lines tested,
three had no detectable BRCA1 levels (Fig. 3a). The cells
that did not express BRCA1 had reduced RAD51 foci
formation upon DNA damage, suggesting a deficient HR
functionality (Fig. 3b,c).
Overactivation of IGF1-R pathway in cancer cells having
deficient HR
It was reported that BRCA1 deficient breast tumors have
higher IGF-1R expression [13, 39]. We thus assessed the
expression of downstream proteins of the IGF-1R path-
way in the breast and ovarian cancer cells. As shown in
Fig. 4a,b, higher levels of p-IGF-1R, IGF-1R, p-IRS-1, p-
AKT, and p-S6 was observed in cells lacking BRCA1
protein expression. Similarly, we have found higher
levels of p-IGF-1R, p-IRS-1, p-AKT and p-S6 in patient
derived ovarian tumor cells without BRCA1 expression,
as shown Fig. 3a.
Increased sensitivity of cancer cells bearing HR deficiency
to an IGF-1Rki
We next evaluated the sensitivity of these cells to IGF-
1Rki by survival assays. Ovarian and breast cancer cells
with functional HR displayed a 40–60 % decrese in cell
survival at a dose of 2.5 μM. In comparison, cells with
low or absent BRCA1 expression, and with a concurrent
HR deficiency, were found to be more sensitive, showing
a survival of only 10–20 % at a dose of 1 μM, as demon-
strated in Fig. 5a,b.
Similar results were observed with patient-derived
ovarian cancer cells, i.e. increased sensitivity to IGF-1Rkiof cells having low HR functionality as compared to cells
capable of forming increased level of RAD51 foci forma-
tion (Fig. 3d). We next evaluated if a correlation existed
between the LC50 IGF-1Rki and the HR cellular func-
tion. Based on the RAD51 foci formation data, we plot-
ted the LC50 of IGF-1Rki against the difference between
the percentage of cells forming RAD51 foci (>5 foci/
cell) with cisplatin treatment and control (no cisplatin
treatment). This ‘x’ value was used as an indication of
the extent of HR functionality for each cell line. As
shown in Fig. 3e, a tendency towards a positive correl-
ation was observed between LC50 IGF-1Rki and HR
functionality of cells, again suggesting that HR-deficient
cells are more sensitive to IGF-1Rki.
IGF-1R inhibition impacts Homologous Recombination
We next evaluated the effect of IGF-1Rki on HR by
assessing the expression RAD51, a crucial player in HR
DNA repair. Interestingly, we observed a reduction of
RAD51 mRNA levels at 16 h in SKOV3 and at 12 h in
BT20 cells. We also observed a reduction of RAD51
mRNA levels in a dose–response manner (Fig. 6b). Next,
using RAD51 foci formation assay, we found that the
cells treated with the 5 μM IGF-1Rki showed decreased
formation of RAD51 foci after induction of DNA dam-
age with 1 μg/ml cisplatin treatment, as compared to
cells treated with 1 μg/ml cisplatin treatment alone, as
shown in Fig. 6c. This reduction was probably due to a
decrease in RAD51 protein levels in response to IGF-
1Rki, as shown in Fig. 6d, suggesting that IGF-1R inhib-
ition directly impacts HR functionality in cancer cells.
Furthermore, phosphorylated proteins of the IGF-1R
pathway were determined as positive controls in SKOV3
and BT20 cells. We found that p-IGF-1R, p-IRS1, p-
AKT and p-S6 protein levels were decreased in the IGF-
1Rki treated cells as compared to the untreated cells as
shown in Fig. 6d. Next, we determined if the protein
interaction between IRS-1 and RAD51 in our cancer
cells was modified after IGF-1Rki treatment using im-
munoprecipitation. As shown in Fig. 6e, levels of IRS-1
associated with RAD51 and vice versa were significantly
reduced in cells treated with IGF-1Rki. Taken together,
these data suggest that IGF-1Rki suppresses RAD51 ex-
pression and thus affects directly HR DNA repair in
cells.
Fig. 4 IGF-1R pathway is over expressed in HR deficient cancer cells. Cellular lysates from a) ovarian and b) breast cancer cells were subjected for
western blot analysis for the indicated proteins involved in the IGF-1R pathway. One representative blot out of three is shown
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to PARP inhibition
It was reported that HR deficient cells are sensitive to
inhibition of PARP [40]. We evaluated whether HR im-
pairment provoked by IGF-1R inhibition confered in-
creased sensitivity to PARP inhibition. As shown in
Fig. 7a,b, we treated SKOV3 and BT20 cells with in-
creasing doses of IGF-1Rki (0.01–5 μM) and PARP in-
hibitor (Olaparib 0.5–5 μM), alone and in combination.
We found decreased survival of cells with combination
treatment as compared to IGF-1Rki and PARP inhibitor
alone. Further, to determine the nature of the interaction
between IGF-1Rki and PARP inhibitor we used theFig. 5 Increased sensitivity of HR deficient cells to IGF-1Rki. Clonogenic surviv
ovarian (a) and breast (b) cancer cells. Results represent the average of four inmultiple drug effects analysis method of Chou and Tala-
lay (see Materials and Methods) [37]. Interestingly, in
both cell lines tested, we observed the combination
treatment to be synergistic, as mentioned in Fig. 7c. The
Combination Index (CI) for SKOV3 was 0.8 (Olaparib
1 μM and BMS 1.5 μM) and 0.67 for BT20 (Olaparib
0.5 μM and BMS 1.26 μM).
Discussion
BRCA1/2 germline mutation carriers are at an increased
risk of developing ovarian and breast cancer [6, 7, 41–
43]. BRCA1 is a transcription factor involved in numer-
ous cellular processes, including DNA damage repair,al assay was performed in the presence of increasing doses of IGF-1Rki in
dependent experiments
Fig. 6 (See legend on next page.)
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Fig. 6 IGF-1R inhibition reduced RAD51 expression both at mRNA and protein levels. Using HR proficient SKOV3 and BT20 cancer cells, quantitative
RT-PCR analysis showed the reduction of RAD51 mRNA levels in cells treated with IGF-1Rki (a) at different times (12 h-24 h) (b) and doses (1-5 μM).
c IGF-1R inhibition decreases cisplatin-induced RAD51 foci formation in these cells (>5 RAD51 foci/nucleus were considered positive). d Treatment with
5uM of IGF-1Rki for 24 h reduces the expression of RAD51 and IGF-1R pathway proteins, determined by Western blot analysis. A representative blot
out of 3 is shown. e After treatment with 5uM IGF-1Rki for 24 h, clarified protein lysates from SKOV3 (e) and BT-20 (f) cells were subjected
to immunoprecipitation. Precipitates were blotted against RAD51 and IRS-1. One representative blot out of 4 is shown. Results represent
the average of four independent experiments. *p value <0.05
Fig. 7 IGF-1Rki and PARP inhibitor combination effect in HR Proficient cancer cells. SKOV3 (a) and BT-20 (b) cancer cells were treated with increasing
doses of IGF-1Rki in the presence of sublethal doses of 1uM (a) or 0.5uM (b) olaparib for 7 days and survival was determined using the clonogenic
assay. c The combination index was calculated where CI < 1 indicates synergy between the two drugs. Data represents the average of
four independent experiments. *p value <0.05
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ing such that variants in this pathway may modify risk of
cancer in women carrying BRCA mutations [12]. Tran-
scriptional suppression of the IGF-1R gene by BRCA1
has also been reported in breast and endometrial cancer,
and loss-of-function mutation of BRCA1 leads to ampli-
fication [44–46] and constitutive activation of the IGF-
1R pathway in breast cancer [13–15]. The data presented
in this manuscript suggests an interaction between the
two pathways, as demonstrated by the enhanced protein
levels of IGF-1R, p-IGF-1R, p-IRS-1, p-AKT and p-S6 in
ovarian and breast cancer cells having loss-of-function
mutations of BRCA1.
We found an increased sensitivity to IGF-1R inhibition
in cells having loss-of function mutations of BRCA1 (HR
deficient) as compared to wild type BRCA1 (HR profi-
cient) cells, with a positive correlation between LC50 of
the IGF-1Rki and HR functionality. This data is consist-
ent with the finding that suppression of IRS-1 inhibits
the growth of BRCA1-deficient tumor cells [47], and that
HR deficient prostate cancer cells (mutated/methylated
BRCA1) are more sensitive to IGF-1R inhibition [48].
Despite the strong rationale around IGF-1R pathway
inhibition, the promising preclinical data and its reason-
able tolerability, the clinical efficacy has been disappoint-
ing [49, 50]. Our study shows that cells with HR
deficiency are more sensitive to IGF-1Rki, suggesting
that this subset of patients could benefit from this tar-
geted therapy. In order to identify these patients, a clin-
ically relevant test is needed. HR functionality was
previously assessed in ascites of ovarian cancer patients
and breast tumor biopsy samples by RAD51 ionizing ra-
diation induced foci assay, and represent a potentially
useful way of functional diagnostic testing to identify pa-
tients with HR deficiency [38, 51]. These patients could
then be selected to be treated with IGF-1Rki therapy,
with a higher likelihood of responding.
Moreover, we found that IGF-1Rki affects HR in ovar-
ian and breast cancer cells by reducing the expression of
RAD51 at the mRNA level, and this subsequently de-
creased RAD51 protein level and its interaction with
IRS-1. This is consistent with the described increased
HR by IGF-1R activation associated to the translocation
of RAD51 to the sites of damaged DNA (nuclear foci)
[52]. To date, the role of IGF-1R inhibition in DNA re-
pair has been reported in several studies [32, 48, 53, 54],
emphasizing the role of IGF-1R inhibition in suppression
of HR, but the mechanism is not fully known. In pros-
tate cancer cells, co-inhibition of epidermal growth fac-
tor receptor and IGF-1R reduced phosphorylation of
IRS-1 and its interaction with RAD51, suppressing HR
and increasing radio-sensitivity [53].
Our data further suggests that IGF-1R inhibition sup-
presses HR by downregulation of RAD51, and that thisallows a strong antitumor activity in combination with
PARP inhibitors in BRCA1 wild-type (HR proficient)
ovarian and breast cancer cells. This is consistent with
our previous work demonstrating that inhibition of the
IGF-1R sensitizes ovarian cancer cells to PARP inhib-
ition [24]. Similar sensitization to PARP inhibition in
TNBCs without BRCA mutations were described with
PI3K blockade [55]. These findings could help improve
the clinical activity of the PARP inhibitors in non BRCA
mutant tumors.
Several factors limit the interpretation of our results.
First, we used commercial cell lines that differ from pa-
tient tumors which are often heterogeneous. In addition,
in vitro results should be interpreted cautiously as the
effective concentration delivered to the cell can vary
from in vivo models, and the effects are evaluated with-
out the interactions with the in vivo microenvironment.
Further steps include xenograft models that will provide
the rationale to investigate the clinical efficacy of dual
PARP and IGF-1R inhibition in cancer cells, an approach
that could expand the subset of patients who may bene-
fit from PARP inhibitors.
Conclusions
Treatment options are limited for patients with high
grade ovarian cancer and metastatic triple negative
breast cancer. Recent work has suggested a role for
BRCA1/2 and defective HR in sporadic ovarian cancer
resulting from somatic mutations or epigenetic mecha-
nisms. Here, we assessed the correlation between IGF-
1R inhibition and HR functionality of breast and ovarian
cancers cells, and observed an increased sensitivity of
HR deficient cancer cells to IGF-1Rki. Moreover, our
data suggest that inhibiting the IGF-1R pathway sup-
presses HR by reduction in expression of RAD51. We
further showed that IGF-1Rki and PARP inhibitors act
in synergy to inhibit cancer cells. Here, we show that
IGF-1R blockade results in HR impairment and
sensitization to PARP inhibition in ovarian and breast
cancer cells without BRCA mutations, providing a ra-
tionale to combine IGF-1R and PARP inhibitors in this
indication and providing new opportunities for the de-
velopment of targeted personalized cancer therapy,
expanding the number of patients that could benefit
from PARP inhibitors.
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